| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb141b396e502bfce986c491d722e401 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5044
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0663
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-58 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-077 |
| filingDate |
2019-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a27028239938d982cbbc3699fce3f74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_079289815e14c50d37a141a1d1742024 |
| publicationDate |
2019-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019213144-A1 |
| titleOfInvention |
Personalized leukemia/lymphoma therapeutic model |
| abstract |
The disclosure is directed to an ex vivo cell culture system and methods of using the cell culture system to identify potential therapeutic agents for the treatment of leukemia or lymphoma, such as chronic lymphocytic leukemia (CLL). The ex vivo culture system comprises (a) a first cell culture comprising bone marrow stromal cells (BMSC) which express one or more exogenous cell signaling molecules; (b) a second cell culture comprising leukemia or lymphoma cells isolated from a human; and optionally (c) one or more soluble cell signaling molecules. |
| priorityDate |
2018-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |